Author:
Wu Guanghao,Su Qihang,Li Jie,Xue Chao,Zhu Jie,Cai Qiuchen,Huang Jingbiao,Ji Shaoyang,Cheng Biao,Ge Hengan
Abstract
Abstract
Background
Tendinopathy is the leading sports-related injury and will cause severe weakness and tenderness. Effective therapy for tendinopathy remains limited, and extracellular vesicles (EVs) derived from adipose tissue-derived mesenchymal stem cells (ADMSCs) have demonstrated great potential in tendinopathy treatment; however, the influence of aging status on EV treatment has not been previously described.
Results
In this study, it was found that ADMSCs derived from old mice (ADMSCold) demonstrated remarkable cellular senescence and impaired NAD+ metabolism compared with ADMSCs derived from young mice (ADMSCyoung). Lower NAMPT contents were detected in both ADMSCold and its secreted EVs (ADMSCold-EVs). Advanced animal experiments demonstrated that ADMSCyoung-EVs, but not ADMSCold-EVs, alleviated the pathological structural, functional and biomechanical properties in tendinopathy mice. Mechanistic analyses demonstrated that ADMSCyoung-EVs improved cell viability and relieved cellular senescence of tenocytes through the NAMPT/SIRT1/PPARγ/PGC-1α pathway. ADMSCyoung-EVs, but not ADMSCold-EVs, promoted phagocytosis and M2 polarization in macrophages through the NAMPT/SIRT1/Nf-κb p65/NLRP3 pathway. The macrophage/tenocyte crosstalk in tendinopathy was influenced by ADMSCyoung-EV treatment and thus it demonstrated "One-Stone-Two-Birds" effects in tendinopathy treatment.
Conclusions
This study demonstrates an effective novel therapy for tendinopathy and uncovers the influence of donor age on curative effects by clarifying the detailed biological mechanism.
Graphical Abstract
Funder
Project of Shanghai Health Commission
National Natural Science Foundation of China
Project of Shanghai Science and Technology Commission
Publisher
Springer Science and Business Media LLC
Subject
Pharmaceutical Science,Applied Microbiology and Biotechnology,Biomedical Engineering,Molecular Medicine,Medicine (miscellaneous),Bioengineering
Reference44 articles.
1. Millar NL, Silbernagel KG, Thorborg K, Kirwan PD, Galatz LM, Abrams GD, Murrell GAC, McInnes IB, Rodeo SA. Tendinopathy. Nat Rev Dis Primers. 2021;7:1.
2. Gomez-Florit M, Labrador-Rached CJ, Domingues RMA, Gomes ME. The tendon microenvironment: engineered in vitro models to study cellular crosstalk. Adv Drug Deliv Rev. 2022;185:114299.
3. Dan M, Phillips A, Johnston RV, Harris IA. Surgery for patellar tendinopathy (jumper’s knee). Cochrane Database Syst Rev. 2019;9:CD013034.
4. Tung KK, Wei JC. Platelet-rich plasma injection vs sham injection and tendon dysfunction in patients with chronic midportion achilles tendinopathy. JAMA. 1975;2021:326.
5. Schneider M, Angele P, Jarvinen TAH, Docheva D. Rescue plan for achilles: therapeutics steering the fate and functions of stem cells in tendon wound healing. Adv Drug Deliv Rev. 2018;129:352–75.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献